The RAS‐signaling‐pathway‐mutation‐related prognosis in B‐cell acute lymphoblastic leukemia: A report from South China children's leukemia group

Abstract The next‐generation sequencing technologies application discovers novel genetic alterations frequently in pediatric acute lymphoblastic leukemia (ALL). RAS signaling pathway mutations at the time of relapse ALL frequently appear as small subclones at the time of onset, which are considered as the drivers in ALL relapse. Whether subclones alterations in the RAS signaling pathway should be considered for risk group stratification of ALL treatment is not decided yet. In this work, we investigate the RAS signaling pathway mutation spectrum and the related prognosis in pediatric ALL. We employed an NGS panel comprising 220 genes. NGS results were collected from 202 pediatric ALL patients. 155 patients (76.7%) harbored at least one mutation. The incidences of RAS signaling pathway mutations are different significantly between T‐ALL and B‐ALL. In B‐ALL, the RAS pathway is mostly involved, and NRAS (17.6%), KRAS (22.7%), and PTPN11 (7.7%) were the three most frequently mutated genes. Co‐occurring mutations of CREBBP and NRAS , FLT3 , or PTPN11 ( p = 0.002, p = 0.009, and p = 0.003, respectively) were found in this cohort. The 3‐year RFS rates for the RAS signaling pathway mutation‐positive and negative cases was 76.5 % versus 89.7 % ( p = 0.012). Four cases relapsed in the lately 3 years were RAS signaling pathway mutation‐positive. RAS signaling pathway mutation is an important biomarker for poorer relapse‐free survival in pediatric B‐ALL patients despite good early MRD levels.